Insulin-like growth factor-1 and risk of Alzheimer dementia and brain atrophy
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received July 30, 2013
- Accepted in final form January 29, 2014
- First Published April 4, 2014.
Article Versions
- Previous version (April 4, 2014 - 13:01).
- You are viewing the most recent version of this article.
Author Disclosures
- Andrew J. Westwood, MD,
- Alexa Beiser, PhD,
- Charles DeCarli, MD,
- Tamara B. Harris, PhD,
- Tai C. Chen, PhD,
- Xue-mei He, MD,
- Ronenn Roubenoff, MD,
- Aleksandra Pikula, MD,
- Rhoda Au, PhD,
- Lewis E. Braverman, MD,
- Philip A. Wolf, MD,
- Ramachandran S. Vasan, MD and
- Sudha Seshadri, MD
- Andrew J. Westwood, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Alexa Beiser, PhD,
NONE
NONE
NONE
NONE
NONE
Brooks Cole, Introductory Applied Statistics, 2005
NONE
NONE
NONE
NONE
NONE
NONE
NIH/NINDS, biostatistician, 2 R01 NS017950-28, 2009-2014 NIH/NIA, biostatistician, 5 R01 AG08122, 2005-2010 NIH/NIA, biostatistician, 2 R01 AG16495, 2005-2010 NIA/NINDS, biostatistician, 1 R01 AG033040-01, 2009-2013 NIH/NHLBI, biostatistician, R01 HL093029-01A1, 2009-2011
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Charles DeCarli, MD,
NONE
NONE
NONE
I am Editor-in-Chief of Alzheimer Disease and Associated Disorders
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
National Institutes of Health
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Tamara B. Harris, PhD,
NONE
NONE
NONE
J of Gerontology: Medical Science, Editorial advisory board member, 2008-present.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Principal Investigator, Age, Gene/Environment Susceptibility-Reykjavik Study, 2002-present, Contact: N01-AG-12100 Principal Investigator, Health, Aging, and Body Composition Study, Contracts: AG-6-2101, AG-6-2103, AG-6-2106, and AG021918, 1998-present.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Tai C. Chen, PhD,
NONE
NONE
NONE
NONE
New potent pro-drug for cancer treatment
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Xue-mei He, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Ronenn Roubenoff, MD,
NONE
NONE
NONE
NONE
NONE
NONE
Dr. Roubenoff is an employee of Novartis Institutes for Biomedical Research, Global Translational Medicine Head for Musculoskeletal Diseases, 4 years.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Aleksandra Pikula, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Rhoda Au, PhD,
Non-profit entity - National Parkinsons Foundation External Advisory Board (March 16-17, 2013); honorarium $7500+travel expenses
NONE
1) non-profit - Korean Epidemiology and Genomic Study 10th Year Anniversary - travel expenses plus $200 honoraria.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NIA, investigator, 5 R01 AG08122 1990-2016; NIA, PI, 2 R01 AG16495 1998-2017; NIA neuropsychologist, 2 R01 NS017950 2002-2014; NINDS, investigator, 1 R01 AG033040, 2009-2013; NIA, neuropsychologist, R01-AG029451 2008-2013 PI, R21-AG036454 2010-2012 neuropsychologist, AG031171-01A2 2009-2014
NONE
Wing Tat Lee Fund, PI, Dec. 2008-Oct. 2009
NONE
NONE
NONE
NONE
NONE
NONE
- Lewis E. Braverman, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Philip A. Wolf, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
N01-HC-25195 (Wolf) 10/01/01-03/31/15 NIH/NHLBI The Framingham Heart Study 2 R01 AG16495 (Wolf) 12/01/98-08/31/17 NIH/NIA MRI, Genetic and Cognitive Precursors of AD and Dementia 2 R01 NS017950-28 (Wolf) 07/01/09-06/30/14 NIH/NINDS Precursors of Stroke Incidence and Prognosis R01 AG08122 (Wolf & Seshadri) 01/01/10-05/31/15 NIH/NIA Epidemiology of Dementia in the Framingham Study 1 R01 AG033040-01 (Wolf) 01/15/09-12/31/13 NIA/NINDS MRI, Cognitive, Genetic & Biomarker Precursors of AD & Dementia in Young Adults R01-AG029451 (Murabito) 05/01/08-04/30/13 NIH/NIA Exceptional Aging Across the Life Span: Framingham Study 1R01NS070307-01(Hylek,PI) 09/30/10 -07/31/13 NIH/NINDS Effect of Statins and Modifiable Factors on Stroke Outcome in Atrial Fibrillation
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Ramachandran S. Vasan, MD and
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NHLBI N0125195, PI, 2010 t date
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Sudha Seshadri, MD
NONE
NONE
NONE
Journal of Alzheimer's Disease, Associate Editor since 2005. Stroke: Editorial Board since 2010. Neurology: Editorial Board since 2011.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NIH/NIA: Grant number: R01 AG08122 (PI: Seshadri, Wolf); role: PI (Multiple PI grant) 08/01/10-07/31/16; NIH/NINDS: Grant number R01 NS017950-28 (Wolf); role: investigator; 07/01/09-6/31/14; NIH/NIA: 1 R01 AG033040-01 (PI: Wolf); role: investigator; 01/15/09-12/31/13; NIH/NIA: Grant number: R01 AG033193(PI: Seshadri); 02/01/09-01/31/17
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- From the Department of Neurology (A.J.W., A.B., A.P., R.A., P.A.W., S.S.) and Sections of Preventative Medicine and Cardiology, Department of Medicine (R.S.V.), Boston University School of Medicine; Department of Biostatistics (A.B.), Boston University School of Public Health, Boston; Framingham Heart Study (A.B., A.P., R.A., P.A.W., R.S.V., S.S.), Framingham, MA; University of California at Davis (C.D.), Sacramento, CA; National Institute on Aging (T.B.H.), Bethesda, MD; Boston University Medical Center (T.C.C., X.-m.H., L.E.B.), Section of Endocrinology, Diabetes, and Nutrition, Boston; Novartis Institutes for Biomedical Research (R.R.), Cambridge, MA.
- Correspondence to Dr. Seshadri: suseshad{at}bu.edu
Article usage
Cited By...
Disputes & Debates: Rapid online correspondence
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.